Patent intelligence · US
US 12077605
Cysteine protease inhibitors and methods of use thereof
Cysteine protease inhibitors and methods of use thereof
Patent details — US 12077605
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 3, 2024
- Expiration
- Aug 29, 2044
- Applicant
- Anixa Biosciences, Inc.
- Claims
- 10
- CPC classes
- A61K, A61K31/245, A61K31/404, A61K31/427
Quick answer
US 12077605 (Cysteine protease inhibitors and methods of use thereof) is held by Anixa Biosciences, Inc.. Status: granted. Granted Sep 3, 2024. Expires Aug 29, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Anixa Biosciences, Inc.
- Grant date
- Expiration
- Claims
- 10
- CPC classes
- A61K, A61K31/245, A61K31/404, A61K31/427, A61K31/4418, A61K31/496
Frequently asked questions
What is US patent 12077605?
US 12077605 (Cysteine protease inhibitors and methods of use thereof) is held by Anixa Biosciences, Inc.. Status: granted. Granted Sep 3, 2024. Expires Aug 29, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12077605?
Anixa Biosciences, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1 pharmaceutical patents for this assignee.
When does US 12077605 expire?
Our index shows an expiration date of Aug 29, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.